StockData
Contineum Therapeutics, Inc. logo

Contineum Therapeutics, Inc. (CTNM) stock

CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/30
$9.55−0.12 (-1.24%)

Close on Nov 17, 2026Market cap $359.28MP/E –Yield –

Contineum Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Contineum Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.01M. For fiscal 2025 it was -$55.31M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$55.31M–
FY2024Dec 31, 2024-$32.85M-269.8%
FY2023Dec 31, 2023$19.35M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.50M–
Q1 FY2026Mar 31, 2026-$16.27M–
Q4 FY2025Dec 31, 2025-$13.04M–
Q3 FY2025Sep 30, 2025-$12.20M–
Q2 FY2025Jun 30, 2025-$15.66M–
Q1 FY2025Mar 31, 2025-$14.41M–
Q4 FY2024Dec 31, 2024-$10.20M–
Q3 FY2024Sep 30, 2024-$6.17M–
Q2 FY2024Jun 30, 2024-$8.50M-120.9%
Q1 FY2024Mar 31, 2024-$7.98M–
Q4 FY2023Dec 31, 2023-$10.70M–
Q3 FY2023Sep 30, 2023-$5.38M–
Q2 FY2023Jun 30, 2023$40.67M–
Q1 FY2023Mar 31, 2023-$5.24M–

More Contineum Therapeutics figures

See a number that looks wrong?